Gossamer bio announces appointment of john quisel, j.d., ph.d., to its board of directors

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced the appointment of john quisel, j.d., ph.d., president and ceo of disc medicine, to its board of directors. “today, we are thrilled to announce that dr. john quisel has joined the gossamer team," said faheem hasnain, chairman, co-founder and ceo of goss.
GOSS Ratings Summary
GOSS Quant Ranking